Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- FY2015 Earnings Roundup - 5: 10 Firms Unveil Mid-Term Biz Plans, Many Play It Safe
June 10, 2016
- Mitsubishi Gas Chemical, Nippon Kayaku Form JV for Antibody, Biosimilar Production
June 10, 2016
- Takeda Gets Worldwide Rights to Theravance’s GI Drug Candidate
June 10, 2016
- Jacques Nathan to Lead Sanofi Japan from July 1
June 10, 2016
- AZ Japan Pres. Baertschi to Become CEO of Grünenthal in October
June 9, 2016
- Takeda, Ultragenyx Ink Strategic Partnership on Rare Genetic Diseases
June 9, 2016
- Shionogi to Transfer 3 Off-Patent Cancer Drugs to Nichi-Iko
June 9, 2016
- FY2015 Earnings Roundup - 4: Generic Biz Strategies Revolving around AG Launches
June 9, 2016
- Kaketsuken Announces Plan for Production Restart, Says Flu Vaccine Output Will Be Lower
June 9, 2016
- Kyowa Kirin, Medgenics Team Up on Severe Pediatric IBD Treatment
June 8, 2016
- FY2015 Earnings Roundup - 3: Japan Market Stagnates despite No Drug Price Revision, Off-Patent Brands Weigh
June 8, 2016
- Takeda, Roivant Form Joint Venture for Women’s Health, Prostate Cancer; Takeda Transfers 2 Investigational Products
June 8, 2016
- FY2015 Earnings Roundup - 2: New Drugs Gain Traction Overseas to Underpin Japan Makers’ Financial Results
June 7, 2016
- PDUFA Date for Naldemedine Set for March 23, 2017
June 7, 2016
- Takecab Most Promoted Drug for 4 Months on End: Anterio
June 7, 2016
- FY2015 Earnings Roundup - 1: Operating Profits of Japan Makers Climb on Global Brands, Royalties
June 6, 2016
- Eisai, Novartis to Join Forces in US Lenvima Promotion for Kidney Cancer
June 6, 2016
- Astellas to Kick Off Global PIII on Xtandi for Triple-Negative Breast Cancer
June 6, 2016
- 27 Japan Drug Makers Derive Record 45.8% of Sales from Overseas Market: Jiho Tally
June 3, 2016
- AbbVie, EA Pharma Initiate Copromotion of Humira in GI Field
June 3, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…